Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00328926 · ClinicalTrials.gov registry record · Phase 4
Luveris® (Lutropin Alfa for Injection) in Women With Hypogonadotropic Hypogonadism (Luteinizing Hormone [LH] Less Than [<] 1.2 International Unit Per Liter [IU/L])
A Phase 4 study, sponsored by EMD Serono.
- Terminated
- Registry status
- Phase 4
- Development phase
- 11
- Enrollment target
NCT00328926 is a Phase 4 study that was terminated before completion, run by EMD Serono. The registered enrollment target is 11 participants.
The verdict
NCT00328926, a Phase 4 study, was terminated before completion, sponsored by EMD Serono.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 11 participants
- Enrollment target
Study Summary
Sponsor has decided to discontinue Luveris® in the United States (US) due to level of customer demand for this product, and not due to any efficacy or safety concerns.
Interventions
- DRUG Placebo
- DRUG Recombinant human chorionic gonadotropin (r-hCG)
- DRUG Luveris® 75 IU
- DRUG Luveris® 25 IU
- DRUG Recombinant human follicle stimulating hormone (r-hFSH)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2006-03 |
| Est. Completion | 2012-05 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00328926
The ClinicalTrials.gov registry entry for NCT00328926 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is EMD Serono, which has 71 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT00328926 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00328926 about?
NCT00328926 is a clinical study titled "Luveris® (Lutropin Alfa for Injection) in Women With Hypogonadotropic Hypogonadism (Luteinizing Hormone [LH] Less Than [<] 1.2 International Unit Per Liter [IU/L])". Sponsor has decided to discontinue Luveris® in the United States (US) due to level of customer demand for this product, and not due to any efficacy or safety concerns.
What is the current status of trial NCT00328926?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 11 participants. The study started on 2006-03. Estimated completion is 2012-05.
What interventions are being tested in trial NCT00328926?
The interventions under investigation include: Placebo (DRUG), Recombinant human chorionic gonadotropin (r-hCG) (DRUG), Luveris® 75 IU (DRUG), Luveris® 25 IU (DRUG), Recombinant human follicle stimulating hormone (r-hFSH) (DRUG).
Who is sponsoring clinical trial NCT00328926?
This trial is sponsored by EMD Serono, which has 71 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.